Wilmington Savings Fund Society FSB Has $8.27 Million Stake in Pfizer Inc. (NYSE:PFE)

Wilmington Savings Fund Society FSB cut its position in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 311,773 shares of the biopharmaceutical company’s stock after selling 11,243 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Pfizer were worth $8,271,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. D Orazio & Associates Inc. grew its holdings in Pfizer by 5.5% in the fourth quarter. D Orazio & Associates Inc. now owns 7,549 shares of the biopharmaceutical company’s stock worth $200,000 after purchasing an additional 391 shares during the period. Kingsview Wealth Management LLC boosted its stake in shares of Pfizer by 28.8% in the 4th quarter. Kingsview Wealth Management LLC now owns 159,281 shares of the biopharmaceutical company’s stock worth $4,226,000 after buying an additional 35,652 shares during the last quarter. Vest Financial LLC increased its position in shares of Pfizer by 15.1% during the 4th quarter. Vest Financial LLC now owns 27,234 shares of the biopharmaceutical company’s stock valued at $723,000 after purchasing an additional 3,573 shares during the last quarter. BayBridge Capital Group LLC grew its position in shares of Pfizer by 2.0% during the 4th quarter. BayBridge Capital Group LLC now owns 39,329 shares of the biopharmaceutical company’s stock valued at $1,043,000 after acquiring an additional 768 shares during the period. Finally, Quattro Financial Advisors LLC increased its position in Pfizer by 6.6% in the fourth quarter. Quattro Financial Advisors LLC now owns 170,781 shares of the biopharmaceutical company’s stock worth $4,507,000 after buying an additional 10,517 shares during the last quarter. 68.36% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research note on Wednesday, December 18th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Wolfe Research initiated coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Finally, Guggenheim lowered their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research note on Wednesday, December 11th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Down 0.3 %

Shares of NYSE PFE opened at $25.76 on Friday. The stock has a market cap of $145.96 billion, a P/E ratio of 18.27, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a 50-day moving average of $26.29 and a 200 day moving average of $27.77.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analysts’ expectations of $17.26 billion. During the same period in the previous year, the firm posted $0.10 EPS. The business’s revenue for the quarter was up 24.7% compared to the same quarter last year. As a group, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.68%. The ex-dividend date of this dividend is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is currently 121.99%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.